| Followers | 905 |
| Posts | 39732 |
| Boards Moderated | 7 |
| Alias Born | 03/22/2016 |
Thursday, December 19, 2024 4:43:57 PM
PSNL...BLOWING UP 6.30 BEAST
Recent PSNL News
- Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium • Business Wire • 05/26/2026 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:04:03 PM
- Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring • Business Wire • 05/20/2026 10:00:00 AM
- Personalis to Participate in Upcoming Investor Events • Business Wire • 05/14/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:52:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:03:04 PM
- Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors • Business Wire • 05/13/2026 10:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/12/2026 08:28:07 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/07/2026 09:01:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:03:48 PM
- Personalis Reports First Quarter Results and Recent Highlights • Business Wire • 05/07/2026 08:01:00 PM
- Personalis to Announce First Quarter 2026 Financial Results • Business Wire • 04/23/2026 08:01:00 PM
- Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 • Business Wire • 04/21/2026 10:00:00 AM
- Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026 • Business Wire • 04/13/2026 10:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 08:07:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 08:03:19 PM
- Personalis to Participate in the 25th Annual Needham Virtual Conference • Business Wire • 04/01/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:57:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:54:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 08:17:21 PM
- Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption • Business Wire • 03/17/2026 08:00:00 PM
- Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® • Business Wire • 03/12/2026 10:00:00 AM
